GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.
Shares of low-float micro-cap stock Exicure are rocketing higher in Wednesday's after-hours session after the company announced that it received an extension from the Nasdaq Hearings Panel.
